Currently Viewing:
Currently Reading
Case Report Describes IgE Myeloma Transformed Into IgE-Producing Plasma Cell Leukemia
January 21, 2020 – Alison Rodriguez
What We're Reading: Opioid Lawsuit in Oklahoma; 9/11 Responders, Elevated Leukemia Incidence; MS Treatment Costs
January 14, 2020 – AJMC Staff
Study Examines Prognostic Subsets of B-Cell Receptor Immunoglobulins in CLL
January 05, 2020 – Alison Rodriguez
Study Investigates Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia
January 01, 2020 – Alison Rodriguez
Patient-Reported Outcomes Considered During FDA Clinical Reviews
December 24, 2019 – Maggie L. Shaw
Study Examines Healthcare Use, Cost in Mantle Cell Lymphoma Treatment
December 23, 2019 – Sara Karlovitch
Breakthrough Increases Efficacy of B-Cell Lymphoid Malignancy Treatment
December 14, 2019 – Gianna Melillo
Is There a Future for CAR T-Cell Therapy in Heart Failure?
December 13, 2019 – Maggie L. Shaw
Pediatric Leukemia Treatment Linked to Increased Risk of Infections, Study Finds
August 16, 2019 – Alison Rodriguez

Case Report Describes IgE Myeloma Transformed Into IgE-Producing Plasma Cell Leukemia

Alison Rodriguez
Researchers describe a recent case report of a diagnosis of lgE monoclonal gammopathy which transformed into myeloma, then into lgE-producing plasma cell leukemia.
An abnormal free light chain ratio must be considered as a possible marker of lgE monoclonal gammopathy, researchers concluded following a recent case report of a diagnosis of lgE monoclonal gammopathy which transformed into myeloma, then into lgE-producing plasma cell leukemia.

The case study, published by Biochemia Medica, involved a 71-year-old male who was followed in Brest, France, from 2015 to 2019. Hypogammaglobulinemia was detected during a systematic check-up in November 2015 and a kappa light chain monoclonal gammopathy was first diagnosed due to an increase of the free kappa/lambda chains ratio. The authors noted that no monoclonal immunoglobulin was detected by either serum protein electrophoresis or immunofixation.

“The IgE-producing variant is the rarest sub-type of multiple myeloma, and plasma cell leukemia is considered to be the rarest and the most aggressive of human monoclonal gammopathies,” the researchers noted. “Plasma cell leukaemia (PCL) is considered to be the rarest of human monoclonal gammopathy, accounting for 0.04 cases per 100,000 persons per year in Europe and also the most aggressive. It can either develop de novo (primary PCL) or evolve as a late-stage complication of MM (secondary PCL, sPCL) occurring in less than 1% of MM cases.”

The patient was diagnosed with plasma cell leukemia following a blood smear in June 2018. Additionally, a monoclonal peak was detected and identified as IgE-kappa. Three years later, an archival sample was taken, revealing the presence of a monoclonal IgE that was missed at diagnosis, and chemotherapy with bortezomib and dexamethasone was introduced to the patient.

Following the diagnosis of leukemia the patient survived 10 months. The researchers suggest that abnormal free light chain could be a possible marker of IgE monoclonal gammopathy, even when there is an absence of a solitary light chain by immunofixation.

Also, the case study suggested that the use of an undilated serum may increase the sensitivity of the immunofixation for the detection of IgE monoclonal gammopathies compared to the 1:3 dilution recommended by the manufacturer.

“The medical laboratory plays an important role in the proper diagnosis and quality of management of MM patients. This case revealed that an abnormal FLC ratio should be considered as a warning signal suggesting the possibility of IgD or IgE myeloma even in the absence of a solitary light chain in IFE,” the study concluded. “Further investigation is warranted to evaluate the diagnostic strategy of systematically testing IgD and IgE with IFE in the presence of an abnormal FLC ratio.”


Galakhoff N, Leven C, Eveillard JR, et al. A case of IgE myeloma transformed into IgE-producing plasma cell leukaemia. Biochem Med (Zagreb). 2020;30(1):010801. doi:10.11613/BM.2020.010801.

Related Articles

Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia
SIRT1 Plays Key Role in Preventing Leukemia Stem Cell Elimination
Celgene Announces Topline Results for Maintenance Therapy in Acute Myeloid Leukemia
Is Vacuolization Clinically Relevant When Examining Acute Myeloid Leukemia Blasts?
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up